Literature DB >> 17823551

Molecular studies of vestibular schwannomas: a review.

D Bradley Welling1, Mark D Packer, Long-Sheng Chang.   

Abstract

PURPOSE OF REVIEW: To summarize advances in understanding the molecular biology of vestibular schwannomas over the past year. RECENT
FINDINGS: The role of the neurofibromatosis type 2 protein, denoted as merlin or schwannomin, in embryonic development, cellular adherence, and in cell proliferation has become better elucidated in the past year. Likewise, the role of merlin in Schwann cell-axon interaction has been studied. Additionally, two comprehensive analyses of the spectrum of human neurofibromatosis type 2 mutations have been compiled which make up a valuable resource in understanding critical regions of the neurofibromatosis type 2 gene. Neurofibromatosis type 2 screening guidelines for young patients with solitary vestibular schwannomas have been published. The role of electromagnetic radiation via cellular and portable telephones as a predisposing factor to vestibular schwannoma formation has also been the topic of several studies. Based on increased knowledge of the pathways in which merlin functions and the available transgenic and xenograft mouse models, preliminary data regarding directed pharmacotherapy are also summarized.
SUMMARY: With increased knowledge of the pathologic mechanisms and interacting proteins associated with merlin, the research community is poised to begin trials of targeted interventions in vitro and in the current mouse models.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823551     DOI: 10.1097/MOO.0b013e3282b97310

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  14 in total

1.  Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.

Authors:  Andrew K Patel; Thomas H Alexander; Ali Andalibi; Allen F Ryan; Joni K Doherty
Journal:  Laryngoscope       Date:  2008-08       Impact factor: 3.325

2.  Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.

Authors:  Abraham Jacob; Janet Oblinger; Matthew L Bush; Victoria Brendel; Griffin Santarelli; Abhik R Chaudhury; Samuel Kulp; Krista M D La Perle; Ching-Shih Chen; Long-Sheng Chang; D Bradley Welling
Journal:  Laryngoscope       Date:  2011-11-22       Impact factor: 3.325

3.  The Novel Small Molecule Inhibitor, OSU-T315, Suppresses Vestibular Schwannoma and Meningioma Growth by Inhibiting PDK2 Function in the AKT Pathway Activation.

Authors:  M E Mercado-Pimentel; S Igarashi; A M Dunn; M Behbahani; C Miller; C M Read; A Jacob
Journal:  Austin J Med Oncol       Date:  2016-04-21

4.  MicroRNA-21 overexpression contributes to vestibular schwannoma cell proliferation and survival.

Authors:  Joseph A Cioffi; Wei Ying Yue; Sabrina Mendolia-Loffredo; Kameron R Hansen; P Ashley Wackym; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2010-12       Impact factor: 2.311

5.  Treatment of vestibular schwannoma cells with ErbB inhibitors.

Authors:  Matthew L Bush; Sarah S Burns; Janet Oblinger; Sholpan Davletova; Long-Sheng Chang; D Bradley Welling; Abraham Jacob
Journal:  Otol Neurotol       Date:  2012-02       Impact factor: 2.311

Review 6.  Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival.

Authors:  Ivan Stamenkovic; Qin Yu
Journal:  Curr Protein Pept Sci       Date:  2010-09       Impact factor: 3.272

7.  Inhibiting p21-Activated Kinase Induces Cell Death in Vestibular Schwannoma and Meningioma via Mitotic Catastrophe.

Authors:  Melania Ester Mercado-Pimentel; Craig Miller; Daniela N Rolph; Edrick F Villalobos; Allison M Dunn; Prithvi M Mohan; Suzu Igarashi; Xiangdang Liu; Macken Yrun-Duffy; Neal K Patel; Cecilia M Read; Ross H Francis; Adelina Isabella Lane; Swaroop Murugesh; Abraham Jacob
Journal:  Otol Neurotol       Date:  2017-01       Impact factor: 2.311

Review 8.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

9.  The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.

Authors:  J Jason Clark; Matthew Provenzano; Henry R Diggelmann; Ningyong Xu; Skylar S Hansen; Marlan R Hansen
Journal:  Otol Neurotol       Date:  2008-09       Impact factor: 2.311

10.  p75NTR is highly expressed in vestibular schwannomas and promotes cell survival by activating nuclear transcription factor κB.

Authors:  Iram Ahmad; Wei Ying Yue; Augusta Fernando; J Jason Clark; Erika A Woodson; Marlan R Hansen
Journal:  Glia       Date:  2014-06-26       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.